Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug ...

Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

Florida Surgeon General Dr. Joseph Ladapo has dismissed concerns that not enough research was done before he and Gov. Ron ...

Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Dr. Scott Rivkees, predecessor to Florida Surgeon General Dr. Joseph Ladapo, says his successor's latest statements are 'part ...

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies ...

As the global population grows older, with senior citizens expected to outnumber children by the 2070s, chronic disease rates ...